DR
Therapeutic Areas
Ternary Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Molecular Glue Degrader | Neuroinflammation | Pre-clinical |
| Molecular Glue Activator | Inflammation | Pre-clinical |
Leadership Team at Ternary Therapeutics
DC
Dr Chris Tame
CEO and Co-Founder
DA
Dr Andrew Potterton
CTO and Co-Founder
DA
Dr Adam Yip
Head of Drug Discovery